Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Research Reports Initiation on Healthcare Stocks -- CVS Health, Express Scripts, UnitedHealth, and Lipocine

PR Newswire November 9, 2016

Lipocine Announces Financial and Operational Results for the Third Quarter of 2016

GlobeNewswire November 8, 2016

Lipocine Announces Issuance of US Patent 9,480,690

GlobeNewswire November 7, 2016

Lipocine Gets A Boost After News From The FDA

Benzinga.com  October 17, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 17, 2016

Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application

GlobeNewswire October 17, 2016

Lipocine's Positive Patent Lawsuit News Not Enough To Lift The Stock

Benzinga.com  October 13, 2016

Clarus Therapeutics Provides Update on Patent Infringement Lawsuit Against Lipocine’s Oral Product for Testosterone Replacement Therapy

GlobeNewswire October 13, 2016

14 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 11, 2016

Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results

Benzinga.com  October 7, 2016

Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021

GlobeNewswire October 7, 2016

10 Biggest Mid-Day Gainers For Friday

Benzinga.com  October 7, 2016

Mid-Day Market Update: Dow Drops Over 100 Points; Gap Shares Rise Following September Sales Numbers

Benzinga.com  October 7, 2016

Mid-Morning Market Update: Markets Open Lower; Silicon Motion Raises Q3 Forecast

Benzinga.com  October 7, 2016

Research Reports Coverage on Generic Drugs Stocks -- SCYNEXIS, Supernus Pharma, Lipocine, and Carbylan Therapeutics

PR Newswire October 5, 2016

Mid-Afternoon Market Update: Dow Falls 150 Points; Himax Technologies Shares Slide After Nomura Downgrade

Benzinga.com  September 26, 2016

Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Benzinga.com  September 26, 2016

Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy

GlobeNewswire September 26, 2016

Lipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 20, 2016

DEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Lipocine Inc. and a Lead Plaintiff Deadline of August 30, 2016 - LPCN

GlobeNewswire August 29, 2016